Unlabelled: Aim of the study was to elucidate value of HAS-BLED and HEMORR2HAGES scales for prediction bleedings in patients receiving long-term warfarin (W) therapy.
Material And Methods: The study involved 119 patients (72 men) aged 60.9+/-9.6 years with atrial fibrillation or venous thromboembolic complications. Follow up period was 5.6 +/-3.4 years. All bleedings were categorized as 1) single bleeding with INR>4.0 during the 1st month of W therapy; 2) any single bleeding after 1st month of W therapy; 3) recurrent bleedings. CYP29 and VKORC1 (G3673A) genotypic variants were determined by PCR. Patients were divided into low (<3 points of HAS-BLED scale, n=58; <4 points.
Download full-text PDF |
Source |
---|
Drugs Aging
October 2018
Department of Internal Medicine, University Hospital of Heraklion "PAGNI", School of Medicine, University of Crete, Voutes, 71110, Heraklion, Crete, Greece.
J Frailty Aging
March 2018
Dr Rónán O'Caoimh, Centre for Gerontology and Rehabilitation, University College Cork, St Finbarrs Hospital, Douglas road, Cork City, Ireland, Email: Telephone: +353214901461, Facsimile: +3534901635.
Background: Atrial fibrillation (AF) is common among frail older adults. Oral anticoagulation (OAC) is particularly challenging for these due to overlapping stroke and bleeding risk factor profiles.
Objective: To compare the utility of stroke and haemorrhage risk-prediction instruments in the treatment of AF among frail older adults.
Unlabelled: Aim of the study was to elucidate value of HAS-BLED and HEMORR2HAGES scales for prediction bleedings in patients receiving long-term warfarin (W) therapy.
Material And Methods: The study involved 119 patients (72 men) aged 60.9 ± 9.
Unlabelled: Aim of the study was to elucidate value of HAS-BLED and HEMORR2HAGES scales for prediction bleedings in patients receiving long-term warfarin (W) therapy.
Material And Methods: The study involved 119 patients (72 men) aged 60.9+/-9.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!